Taylon A, Blackard W G
Horm Metab Res. 1982 Dec;14(12):623-6. doi: 10.1055/s-2007-1019102.
Insulin binding to monocytes was assessed before and after plasma insulin suppression by diazoxide in 14 obesity-related diabetic subjects. Four of the five patients with mild carbohydrate intolerance (FBS less than 150 mg%) and hyperinsulinism exhibited low monocyte insulin binding. Despite an increase in insulin binding after 7 days of diazoxide therapy, no improvement in carbohydrate tolerance could be demonstrated. Lack of improvement may have been related to persistent diazoxide effect. An additional group of 4 patients with low plasma insulin values and more severe carbohydrate intolerance (FBS greater than 150 mg%) had high monocyte insulin binding. This group, as well as a group of patients with intermediate insulin responses, tolerated diazoxide poorly and developed moderate ketonuria or severe hyperglycemia (plasma glucose greater than 350 mg%) necessitating discontinuation of the drug after 3-6 days. The studies in these patients suggest that obesity-related diabetes may be characterized early by mild elevation of plasma glucose, hyperinsulinism and impaired monocyte insulin binding. As beta cell exhaustion occurs, more severe hyperglycemia intervenes and insulin binding to monocytes increases.
在14名肥胖相关性糖尿病患者中,评估了用二氮嗪抑制血浆胰岛素前后单核细胞的胰岛素结合情况。5例轻度糖耐量异常(空腹血糖低于150mg%)和高胰岛素血症患者中有4例表现出单核细胞胰岛素结合率低。尽管二氮嗪治疗7天后胰岛素结合增加,但糖耐量并无改善。缺乏改善可能与二氮嗪的持续作用有关。另外一组4例血浆胰岛素值低且糖耐量异常更严重(空腹血糖高于150mg%)的患者,单核细胞胰岛素结合率高。该组以及一组胰岛素反应中等的患者,对二氮嗪耐受性差,出现中度酮尿或严重高血糖(血浆葡萄糖高于350mg%),3 - 6天后需要停药。对这些患者的研究表明,肥胖相关性糖尿病早期可能表现为血浆葡萄糖轻度升高、高胰岛素血症和单核细胞胰岛素结合受损。随着β细胞功能衰竭的发生,会出现更严重的高血糖,且胰岛素与单核细胞的结合增加。